People channel feed

Klick Health hires mar­ket ac­cess chief with Big Phar­ma ré­sumé

Last year
Marketing

NIH nom­i­nee Mon­i­ca Bertag­nol­li clears Sen­ate pan­el with bi­par­ti­san sup­port de­spite Sanders’ drug pric­ing qualms

Last year
Pharma
FDA+

Am­gen to cut 350 staffers fol­low­ing $28B Hori­zon takeover

Last year
Pharma

Idor­sia lays off up to 300 peo­ple, plans for pipeline pri­or­i­ti­za­tion in ef­fort to ex­tend cash run­way

Last year
Pharma

Bio­gen CEO Chris Viehbach­er: Im­munol­o­gy is a nat­ur­al fit at biotech, calls for 'rein­ven­tion'

Last year

Q&A: Joe Jimenez talks about sal­vaging ‘stuck’ drugs and why a sub­stance abuse treat­ment could be worth bil­lions of dol­lars

Last year

NIH di­rec­tor nom­i­nee Bertag­nol­li skirts drug pric­ing ques­tions at con­fir­ma­tion hear­ing

Last year
Pharma
FDA+

Nkar­ta trims head­count as it sets sights on au­toim­mune cell ther­a­py

Last year
Cell/Gene Tx

Bellerophon's board ap­proves liq­ui­da­tion plan, leaves Nas­daq af­ter lay­offs and tri­al fail­ures

Last year
Financing

Ex­clu­sive: Hori­zon CEO Tim Wal­bert talks M&A, FTC post-Am­gen deal close

Last year
Pharma

#Eu­ro­Bio23: The down­turn, tak­ing risks and the ‘biotech mafia’

Last year
Financing
Deals

Bio­gen cuts al­most one-third of Reata's staff fol­low­ing $7B buy­out

Last year
Pharma

Wal­greens hires long­time Cigna ex­ec­u­tive Tim Went­worth as CEO

Last year
Health Tech

Sana nar­rows fo­cus to ex vi­vo cell ther­a­pies, lays off 29% of staff to reach key clin­i­cal da­ta

Last year
R&D
Cell/Gene Tx

Pfiz­er cuts jobs at Boul­der, CO, re­search fa­cil­i­ty

Last year
Pharma

Ex­clu­sive: Ver­tex CSO David Alt­shuler talks non-opi­oid pain pills, AI and the myth of break­throughs

Last year
R&D

Ab­cam lays out de­tails be­hind $5.7B Dana­her ac­qui­si­tion, takeover at­tempts by founder and for­mer CEO

Last year
Deals

Dave Lennon's CEO ad­ven­ture goes from pre­clin­i­cal to com­mer­cial; GSK vet em­barks on new Odyssey with Gary Glick

Last year
Peer Review

At­se­na pri­or­i­tizes reti­nal gene ther­a­py pipeline, trims staff as ex­ist­ing in­vestors re­fu­el the biotech 

Last year
Cell/Gene Tx

Im­pel con­sid­ers strate­gic al­ter­na­tives, takes out $2.5M loan to con­tin­ue op­er­at­ing

Last year
Pharma

UniQure halves re­search, lays off 20% while CSO de­parts in ma­jor re­vamp

Last year
R&D
Cell/Gene Tx

A con­ver­sa­tion with No­bel Prize win­ner Katal­in Karikó on re­jec­tion, fi­nal­ly be­ing rec­og­nized and her mR­NA work

Last year

Lil­ly's di­a­betes and obe­si­ty leader to re­tire in broad­er lead­er­ship shuf­fle as CSO Dan Skovron­sky takes on im­munol­o­gy role

Last year
Pharma

Kezar changes CEOs, lays off 41% of staff and halts pre­clin­i­cal R&D to ex­tend cash run­way

Last year
R&D
First page Previous page 18192021222324 Next page Last page
A service from the Financial Times